{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:01:56Z","timestamp":1790949716641,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.autrev.2021.102830","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:18:29Z","timestamp":1618939109000},"page":"102830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review"],"prefix":"10.1016","volume":"20","author":[{"given":"Esther F.","family":"Vicente-Rabaneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Atienza-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102830_bb0005","doi-asserted-by":"crossref","first-page":"759760","DOI":"10.1155\/2013\/759760","article-title":"The multifaceted aspects of interstitial lung disease in rheumatoid arthritis","volume":"2013","author":"Cavagna","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2021.102830_bb0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0015","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0020","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0030","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0035","doi-asserted-by":"crossref","first-page":"102447","DOI":"10.1016\/j.autrev.2019.102447","article-title":"Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u04e7gren\u2019s syndrome: a systematic review from the Italian Society of Rheumatology","volume":"19","author":"Sambataro","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0040","doi-asserted-by":"crossref","first-page":"102355","DOI":"10.1016\/j.autrev.2019.102355","article-title":"Interstitial lung disease associated with anti-PM-Scl antibody: a single center experience","volume":"18","author":"Ussavarungsi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2021.102830_bb0050","first-page":"344","article-title":"Patterns of interstitial lung disease and mortality in rheumatoid arthritis","volume":"56","author":"Zamora-Legoff","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0055","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology biologics register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0070","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102830_bb0075","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0080","first-page":"2000337","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","author":"Juge","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2021.102830_bb0085","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/kez177","article-title":"The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment","volume":"58","author":"Duarte","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2021.102830_bb0095","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keaa117","article-title":"Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis","volume":"59","author":"Khoo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0100","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102830_bb0105","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102830_bb0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/RHU.0000000000000084","article-title":"Abatacept therapy in rheumatoid arthritis with interstitial lung disease","volume":"20","author":"Mera-Varela","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102830_bb0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","article-title":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","volume":"54","author":"Nakashita","year":"2016","journal-title":"Respir Investig"},{"key":"10.1016\/j.autrev.2021.102830_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/14397595.2015.1109578","article-title":"The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice","volume":"26","author":"Mochizuki","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0145","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2169\/internalmedicine.2226-18","article-title":"Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis","volume":"58","author":"Kurata","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2021.102830_bb0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2019.11.010","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","volume":"50","author":"Kang","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jcm9010277","article-title":"Safety of Abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2021.102830_bb0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-020-05227-9","article-title":"Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis","volume":"40","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0165","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2021.102830_bb0170","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102830_bb0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0185","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2021.102830_bb0195","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax."},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102830_bb0200","first-page":"968","article-title":"Abatacept in combination with metotrexate in patients with rheumatoid arthritis associated to interstitial lung disease: national multicenter study of 263 patients. Poster #SAT0075","volume":"79","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102830_bb0205","first-page":"943","article-title":"Poster #SAT0035. Response to abatacept of different patterns of interstitial lung disease in rheumatoid arthritis: national multicenter study of 263 patients","volume":"79","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0210","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","article-title":"Systemic rheumatic diseases: from biological agents to small molecules","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0215","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0220","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.autrev.2019.03.008","article-title":"The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: a systematic literature review","volume":"18","author":"Ursini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/acr2.1034","article-title":"Safety of Abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials","volume":"1","author":"Simon","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-018-1694-9","article-title":"T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis","volume":"20","author":"Boleto","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102830_bb0235","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.4049\/jimmunol.163.12.6794","article-title":"Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis","volume":"163","author":"Isra\u00ebl-Assayag","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102830_bb0240","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.yexmp.2011.09.010","article-title":"The effect of CTLA-4Ig, a CD28\/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis","volume":"91","author":"Jim\u00e9nez-Alvarez","year":"2011","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.autrev.2021.102830_bb0245","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/annrheumdis-2012-201944","article-title":"HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker?","volume":"72","author":"Furukawa","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-211512","article-title":"HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study","volume":"76","author":"Bluett","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0260","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780401016","article-title":"Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0265","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/s10165-010-0280-z","article-title":"Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort","volume":"20","author":"Shidara","year":"2010","journal-title":"IORRA Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarc\u00f3n","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102830_bb0275","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","article-title":"Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0280","first-page":"43","article-title":"Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-\u03b1 agents","volume":"35","author":"Detorakis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2021.102830_bb0290","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0295","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3899\/jrheum.150674","article-title":"Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials","volume":"43","author":"Conway","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0300","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","article-title":"Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sawada","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0305","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2177\/jsci.35.433","article-title":"A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept","volume":"35","author":"Wada","year":"2012","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.autrev.2021.102830_bb0310","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5152\/eurjrheum.2015.0037","article-title":"A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept","volume":"3","author":"Do\u011fu","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0320","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/s10165-010-0406-3","article-title":"Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis","volume":"21","author":"Koike","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0325","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/14397595.2013.843760","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients","volume":"24","author":"Koike","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102830_bb0335","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.autrev.2021.102830_bb0340","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102830_bb0345","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.autrev.2021.102830_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000473","article-title":"Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic","volume":"3","author":"Druce","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2021.102830_bb0355","article-title":"Organizing pneumonia induced by tocilizumab in a patient with rheumatoid arthritis","volume":"12","author":"Gouveia","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2021.102830_bb0360","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00296-010-1525-z","article-title":"A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab","volume":"32","author":"Kawashiri","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102830_bb0365","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","article-title":"Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study","volume":"36","author":"Akiyama","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102830_bb0370","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0375","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.autrev.2021.102830_bb0380","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2021.102830_bb0385","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3390\/jcm9103070","article-title":"Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review","volume":"9","author":"Atienza-Mateo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2021.102830_bb0390","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0395","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0400","doi-asserted-by":"crossref","first-page":"102453","DOI":"10.1016\/j.autrev.2019.102453","article-title":"Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review","volume":"19","author":"Bellan","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0405","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.autrev.2020.102742","article-title":"Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development","volume":"20","author":"Karakontaki","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102830_bb0410","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102830_bb0415","first-page":"1414","article-title":"AB0237 are there differences in clinical profile and treatment among 2 different intercontinental cohorts of patients with rheumatoid arthritis-associated interstitial lung disease?","volume":"79","author":"Azuaga-Pi\u00f1ango","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102830_bb0420","series-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Manejo de Pacientes con Artritis Reumatoide","author":"Grupo de trabajo de la GUIPCAR","year":"2019"},{"key":"10.1016\/j.autrev.2021.102830_bb0425","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102830_bb0430","unstructured":"APRIL (AbatacePt in Rheumatoid Arthritis-ILD) trial. ClinicalTrials.gov Identifier: NCT03084419. ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03084419?term=abatacept+AND+rheumatoid+arthritis&cond=Interstitial+Lung+Disease&draw=2&rank=1; 2017 [accessed 31 December 2020]."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:21:52Z","timestamp":1761600112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1568997221001026"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102830","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102830"}}